Lineage Cell Therapeutics, Inc.
corporate_fare Company Profile
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for LCTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for LCTX spans 4, 8-K.
Recent high-impact activity:
- Broadwood's Bradsher Buys 1M LCTX Shares for $770,700 Open-Market
- Lineage Closes NeuroAirmid Buy, Adding Clinical-Stage Huntington's Program HUNT1
Financial Snapshot
Short Interest & Short Volume
19.27 days to coverFINRA reported short interest of 24,348,055 shares in LCTX as of the October 30, 2026 settlement, a 6.1% decrease from the prior period — about 19.3 days to cover at its recent average daily volume. On November 20, 2026, 42.7% of LCTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.